BioScreening - organic compounds for screening

30.11.2003 November 2003 News Archive

11/25/03 -Tranzyme and NeoGenesis
Have expanded their collaboration to include additional genes of therapeutic interest and will utilize Tranzyme's TExT™ in support of the chemical genomics program at NeoGenesis. NeoGenesis will provide additional sets of disease-associated gene sequences of therapeutic interest. Tranzyme will deliver these genes into different mammalian cell lines and express the proteins using its protein expression technology (TExT™). NeoGenesis will deploy the purified proteins in ALI (Automated Ligand Identification System), their ultra-HTS platform. 

11/19/03 - ExonHit Therapeutics
Announced that Allergan, a global specialty pharmaceutical company, has initiated HTS on a target generated pursuant to a 10 month old strategic alliance between the companies. ExonHit is a privately held company that discovers neurodegenerative and cancer therapeutics and diagnostics based on alternative RNA splicing. 

11/11/03 - MDL
Has released MDL® Plate Manager, for tracking, sorting, and managing plate and sample information. A request queue aids in anticipating material demand, prioritizing orders and predicting workflows, resolving supply chain bottlenecks. The system ensures sample quality and reduces retesting by accurately tracking both freeze/thaw cycles and shelf life. 

11/11/03 - Tecan
Is co-operating with Corning to offer an automation solution for plate sealing, unsealing and resealing 96- and 384-well microplates. The system combines Corning®'s Robolid™, a microplate seal that incorporates a silicone capmat into a standard polystyrene plate lid, with Tecan's Te-Lidder, an accessory designed for utilizing the Robolid technology on Tecan Workstations and TRAC Robotic Systems.

11/3/03 - Dharmacon/Akceli
Announced a research collaboration to study the utility of combining two technologies: siRNA-mediated gene silencing and whole-well reverse transfection. The companies believe that the combination of these technologies could to advance high-throughput cell-based gene function analysis, target validation and drug discovery. 

11/3/03 - Peakdale Molecular/De Novo Pharmaceuticals
Announced significant results six months into their strategic alliance to design and supply novel compounds, specifically targeted towards the discovery of new molecules active at GPCRs. As a result of the collaboration, a variety of family based extended pharmacophores have been developed, using QUASI2™, for sub-families of the GPCR class of biological targets. 

new | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003